Boehringer settles US off-label marketing cases

21 December 2017

Boehringer Ingelheim Pharmaceuticals Inc (BIPI) has agreed to distribute $13.5 million among all 50 US states and the District of Columbia to end allegations that it marketed four of its prescription drugs for off-label uses, attorneys general announced Wednesday.

This resolves claims by state attorneys general that this US subsidiary of German family owned drugmaker Boehringer Ingelheim used deceptive and misleading marketing to promote the use of four of its drugs for unapproved purposes.

The settlement resolves allegations that BIPI unlawfully marketed the drugs Aggrenox (aspirin/extended-release dipyridamole), Combivent (albuterol and ipratropium), Atrovent (ipratropium) and Micardis (telmisartan) for a variety of non-Food and Drug Administration-approved indications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK